Maziar Eslami Farsani
Neurology · Riverside, CANPI 1831585140
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 466 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,339, more than ten times the $122 reported in 2020.
Across 466 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- AbbVie$2K
- Biogen$2K
- EMD Serono, Inc.$2K
- AstraZeneca$635
- Sanofi$472
- plus $2K from 25 others
Across 4 payments — averaging $95,144 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$381K
What the payments were for
- Consulting fees$1501%
- Food & beverage$10,89698%
- Education$1011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 134 | $2,581 |
| AbbVie(2 entities) | 137 | $1,731 |
| Biogen | 52 | $1,693 |
| EMD Serono, Inc. | 27 | $1,628 |
| AstraZeneca | 17 | $635 |
| Sanofi | 7 | $472 |
| Teva Pharmaceuticals USA, Inc. | 12 | $341 |
| Amgen | 5 | $285 |
| Argenx US, Inc. | 8 | $240 |
| TG Therapeutics, Inc. | 5 | $225 |
| Avanir Pharmaceuticals, Inc. | 12 | $152 |
| Lilly USA, LLC | 6 | $133 |
| UCB, Inc. | 3 | $111 |
| SK Life Science, Inc. | 3 | $110 |
| Lundbeck LLC | 4 | $102 |
| Otsuka America Pharmaceutical, Inc. | 5 | $96 |
| Amneal Pharmaceuticals LLC | 4 | $93 |
| Genentech USA, Inc. | 3 | $78 |
| Bristol Myers Squibb | 4 | $75 |
| Supernus Pharmaceuticals, Inc. | 3 | $64 |
| Corium, LLC | 2 | $59 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Eisai Inc. | 2 | $39 |
| Pfizer | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Livanova USA, Inc. | 1 | $25 |
| Neurelis, Inc. | 1 | $21 |
| Boston Scientific | 1 | $15 |
| Tanabe Pharma America, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,147 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 12 | $436,990 |
| Kesimpta PenOfatumumab | 25 | $232,532 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 22 | $180,234 |
| CopaxoneGlatiramer Acetate | 27 | $156,658 |
| Glatiramer Acetate | 11 | $16,021 |
| Dalfampridine ErDalfampridine | 14 | $3,439 |
| Levetiracetam | 89 | $2,243 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 79 | $2,000 |
| Memantine Hcl | 118 | $1,966 |
| Atorvastatin Calcium | 137 | $1,254 |
| Duloxetine Hcl | 48 | $1,024 |
| Gabapentin | 82 | $977 |
| Carbamazepine ErCarbamazepine | 22 | $530 |
| Baclofen | 32 | $524 |
| Primidone | 29 | $388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $635 | $436,99012 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $341 | $156,65827 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $93 | $33212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.
Other neurology in Riverside
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.